Release Date: Monday, July 9, 2018
Expiration Date: Tuesday, July 9, 2019

Educational Overview
Antimicrobial-resistant Gram-negative bacteria continue to challenge clinicians. Several pathogens have been identified by the CDC and WHO that present serious healthcare threats, including ESBL-producing and carbapenem-resistant Enterobacteriaceae as well as multidrug-resistant P. aeruginosa. Addressing the issue of antimicrobial resistance requires a multifaceted approach that involves timely diagnosis and optimal use of traditional and newer antimicrobials that overcome various mechanisms of resistance. Healthcare providers involved in the management of serious bacterial infections must stay up-to-date on evidence-based approaches to optimize patient care. This program reviews the current landscape of priority Gram-negative bacteria and provide guidance on utilizing rapid diagnostic approaches and newer antimicrobial agents aimed at improving clinical outcomes.

Target Audience
Addressing the challenges of priority Gram-negative bacteria requires an interprofessional approach that includes all healthcare providers involved in the prevention, diagnosis, and management of patients with or at risk for these infections. Therefore, this continuing medical education activity targets a variety of healthcare providers that include ID physicians, infection control specialists, hospital epidemiologists, hospitalists, clinical microbiologists, nurses, and clinical pharmacists.


Learning Objectives
Upon completing this activity, participants will be able to:

  • Discuss current epidemiological trends and resistance mechanisms of priority Gram-negative bacteria and their impact on clinical outcomes
  • Assess the value of rapid diagnostic techniques in promoting pathogen-specific therapy
  • Evaluate the potential role of new and emerging antimicrobial agents in targeting antimicrobial-resistant Gram-negative pathogens

Educational Format

This Online Presentation is based on the Satellite Symposium presented at ASM Microbe in Atlanta, GA on June 9, 2018.
The following topics are covered:

  • Challenges of High Priority Pathogens
  • Understanding the Current MDR Gram-negative Landscape
  • Tools Targeting Priority Pathogens

Note: If you have received credit for attending the live program by the same name, you are not eligible to apply for credit for this online version.


Keith A. Rodvold, PharmD, FCCP, FIDSA

Professor of Pharmacy Practice and Medicine
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, IL




AccreditationThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AccreditationCenter for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credits for participating in this activity.

ACPE UAN: 0473-9999-18-007-H01-P
Activity type: Knowledge-based


For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CME/CPE information including target audience, learning objectives, and disclosures.
  2. Review the activity in its entirety.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. Pharmacists: The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit
  6. Physicians: Certificate of Credit will be emailed to you within 4 weeks.


Disclosure of Conflicts of Interest
In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.


Keith A. Rodvold, PharmD has relevant financial relationships with the following commercial interests:
Advisory Board: Achaogen, Bayer, The Medicines Company, Motif Bio PLC, Paratek, Shionogi, Theravance Biopharma, Melinta Therapeutics, Spero Therapeutics; Meiji; Zavante Therapeutics, Tetraphase

Consultant: Achaogen; Entasis Therapeutics, GlaxoSmithKlein; Melinta Therapeutics; The Medicines Company; Paratek; Shionogi; Spero Therapeutics; Wockhardt; Zavante Therapeutics

Research Support: Allergan, Theravance Biopharma

Speakers Bureau: Merck & Co., Inc.; Allergan; The Medicines Company; Melinta Therapeutics 

Dr. Rodvold discusses off-label uses of the following: Ceftazidime-Avibactam; Ceftolozane-Tazobactam; Meropenem-Vaborbactam; Imipenem-Relebactam; Plazomicin; IV Fosfomycin; Eravacycline; Cefiderocol; Aztreonam-Avibactam; Cefepime-Zidebactam; Sulbactam-ETX2514; Murepavadin

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2018 Vemco MedEd. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

By clicking below, I acknowledge that I have read the entire CME/CPE information.